EL.En. Sells the Scissors, Keeps the Scalpel
Cutlite's exit pushes medical to 92% of revenue and EBITDA margin past 19% — but a global tariff-refund wave the company only watches from the sidelines and a stubborn hair-removal bleed frame the second-half test.
ELN.MI · Earnings Call · 2026-09-11
The pivot: selling the cutting arm to buy focus
EL.En.'s first half of 2026 was really two stories: a laser business that keeps compounding margins, and a company quietly shrinking itself into a purer medical play. In early August, management finalized the sale of its majority stake in Cutlite Penta — the head of the Cutting division — plus the residual Laser Cutting business to market leader TRUMPF. Andrea Cangioli framed it as strategic surgery: “the strategic repositioning effect of the sale on our business scope with the medical sector's weight within our revenues growing from 72% in 2025 to 92% in the first half of 2026 according to the new perimeter.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11
The divested unit was never the point. It generated roughly EUR 121 million of 2025 revenue but only about EUR 2 million of EBIT — essentially break-even net of interest on EUR 16 million of debt. Cangioli admitted the asset had been "struggling," held hostage for over two years by an on-again, off-again M&A process that competitors used as ammunition against it. The deal's price is performance-linked, so it books a loss now; the financial release of that net debt is the immediate prize, and the strategic clarity is the real one.
Where the money actually improved
The optics of the reported half are muddied by IFRS 5 discontinuation accounting — Cutlite was carved out only at June 30, so the comparison periods are uneven. Strip that away and the operating story is loud. Group revenue reached EUR 246 million, up more than 9%. The margin line is where it gets interesting: “EBITDA amounted to EUR 48.7 million, up over 30% from EUR 37.5 million in the first half 2025. EBITDA margin increased from 16.6% in 2025 to 19.8% in 2026.” — Enrico Romagnoli, CFO · 2026-09-11 EBIT climbed to EUR 43.4 million from EUR 31.6 million, lifting EBIT margin from 14% to 17.6%, and net income rose 45% to EUR 26.1 million.
The mix is doing the work. Operating expenses fell as a share of sales from 11.8% to 10.9%, staff cost intensity dropped from 20% to 19.1% — textbook operating leverage. Within medical, Surgical applications grew 15% on urology, Aesthetics rose 11% despite a shrinking hair-removal category, and the recurring revenue engine stands out: sterile optical fiber sales rose 12.1% and now represent nearly 60% of the medical services line, a far stickier, higher-margin stream than selling another laser system. Quanta System's new U.S. distribution hub, live since April, already added about EUR 6 million in the second quarter alone.
The guidance illusion — and the global tariff wave
The most revealing moment was Cangioli defending a guidance that looks underwhelming on its face. By keeping the same >5% revenue growth and EBIT-margin improvement targets despite removing the weakest unit, the benchmark got tougher — which means the second half must be stronger, not weaker: “by confirming the numbers of the guidance with a different benchmark, we are confirming that the results in the second half will be extremely strong.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11
On tariffs, EL.En. is a spectator to a theme that has become one of the loudest cross-market signals of the quarter. Know Trend's global keyword set is dominated by Net tariff refunds, and a wave of reporters — AEO, CULP, DBI, M, LAKE, HOFT, VNCE — have booked reversals. EL.En.'s own distributors got reimbursed for the first-round tariffs the Supreme Court struck down, but the company explicitly did not: “we are not directly operating any activity in the U.S. and the tariffs were levied and paid by our distributors.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11 So while peers bank Tariff Refund checks, EL.En.'s benefit shows up only indirectly, in the health of its distribution partners and a Quanta U.S. operation it now owns outright.
What is fading — and what is being copied
The recurring theme that refuses to die is hair removal, which has now been a drag for several years and still accounts for roughly a third of Aesthetic system sales. The structural erosion is familiar from prior calls, where management pinned part of it on Cynosure exiting the Elite iQ line after merging with Lutronic: “part of the decline in hair removal is due to the fact that Cynosure new property, new management is basically discontinuing the product line.” — Andrea Cangioli · 2025-09-11 The offset is the flagship anti-aging franchise. Onda Pro is growing so well that it now has an unwanted tribute market: “This is why I'm mentioning to you, which lists 19 copies available on the market for to Onda Pro.” — Andrea Cangioli, Chief Executive Officer (CEO) · 2026-09-11 That is both a validation and a warning — the Far East has industrialized imitation, and management is fighting it with legal means while leaning on hair removal-independent anti-aging and a widening installed base to keep the higher-margin mix intact.
Geographic friction persists too. Middle East aesthetics — a key region — remains weaker than last year amid war-related disruption, and the company's Dubai Derma booth stood largely empty. Cangioli's answer on whether to use the swelling cash pile for a transformational deal stayed true to form, echoing the caution he voiced last November: “we are talking of small transaction, but we have both technological and sales solutions and sales opportunities.” — Andrea Cangioli, CEO · 2025-11-17
The takeaway: EL.En. is executing a clean, self-funded strategic pivot — trading a low-margin industrial business for a 92%-medical, 19.8%-EBITDA-margin machine. The risks are structural, not cyclical: a compressing hair-removal category it cannot fully escape, a competitive flood of imitators in its best product, and a tariff-refund windfall it can only watch from the bleachers. The absence of any price-tape context leaves the setup unresolved — but a company that shrinks revenue scope while raising its margin guide is worth watching into the second half.